AdAlta Limited (ASX:1AD)

Australia flag Australia · Delayed Price · Currency is AUD
0.0050
+0.0010 (25.00%)
Aug 22, 2025, 4:10 PM AEST
25.00%
Market Cap5.56M
Revenue (ttm)973.02K
Net Income (ttm)-4.94M
Shares Out1.11B
EPS (ttm)-0.01
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume6,410,928
Average Volume4,275,777
Open0.0050
Previous Close0.0040
Day's Range0.0040 - 0.0050
52-Week Range0.0020 - 0.0240
Beta-0.14
RSI81.80
Earnings DateAug 27, 2025

About AdAlta

AdAlta Limited, a clinical stage biotechnology company, discovers and develops protein and cell-based therapeutics by its i-body platform in Australia. Its lead product is AD-214, which is in Phase II clinical trial for the treatment of fibrosis diseases, including idiopathic pulmonary fibrosis, eye fibrosis, and fibrosis diseases of the liver, skin and kidney, as well as for the treatment of age-related macular degeneration. AdAlta Limited has collaborative partnerships with GE Healthcare Technologies Inc to develop i-body enabled PET imaging ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2006
Employees 9
Stock Exchange Australian Securities Exchange
Ticker Symbol 1AD
Full Company Profile

Financial Performance

In 2024, AdAlta's revenue was 1.74 million, a decrease of -49.91% compared to the previous year's 3.47 million. Losses were -5.38 million, 10.9% more than in 2023.

Financial Statements

News

There is no news available yet.